What's breaking now, across thousands of outlets.
AnaCardio has secured €62.5 million ($70.9 million) in a Series B fundraise to help prepare its chronic advanced heart failure drug for registrational development. The cash should give the Stockholm-based biotech a runway “well into ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Mayo Clinic researchers led a multicenter study that found dividing radiation into several treatments, known as fractionated stereotactic radiosurgery, reduced the risk of cancer returning after…
The Wegovy maker has signed a deal to license an experimental obesity pill from China’s Jiangsu Hengrui Pharmaceuticals as it seeks to regain share of the global GLP-1 market.
Khyber Pakhtunkhwa has reported another polio case, taking the province’s total to four this year. The latest case involves a 17-month-old girl from Domel tehsil in Bannu district.
When Taylor Swift's private jet usage made headlines, climate-conscious fans faced a dilemma. A new study reveals how young fans use psychological defense mechanisms to justify the pop star's carbon…
The Supreme Court clarified the forensic audit's focus is on Fortis Healthcare Holdings Private Limited and the Singh Brothers. This audit is not a broad inquiry into the dealings of other banks.
Novo has signed its fourth weight loss-focused pact of the year, this time tapping a preclinical GLP-1/GIP receptor agonist from China’s Hengrui that could be dosed as little as once a week.
